Physician profile
Sheena E Chand
NPI 1871739847
$7,143.78
in general payments reported to CMS, 2019-2025
27 companies · $869 in 2025
The $869 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,307 · 2022: $1,362 · 2023: $2,395 · 2024: $1,210 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600 · Consulting Fee: $675 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,599.62 |
| Consulting Fee | $675.00 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $998.29 | 2021-2025 | Adbry |
| Abbvie INC. | $863.29 | 2021-2025 | |
| Amgen INC. | $632.84 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $621.36 | 2021-2024 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $516.90 | 2022-2025 | |
| Janssen Biotech, INC. | $433.25 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $412.41 | 2021-2023 | Ilumya, Winlevi |
| Genzyme Corporation | $407.26 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $307.54 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $246.69 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $230.00 | 2022-2024 | Sotyktu |
| Allergan, INC. | $212.72 | 2022 | |
| Lilly USA, LLC | $201.85 | 2021-2024 | Taltz, Olumiant |
| Almirall LLC | $186.33 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $173.22 | 2021-2023 | Jublia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $143.56 | 2021-2023 | |
| Incyte Corporation | $142.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $105.83 | 2021-2024 | Dupixent |
| Organon LLC | $81.81 | 2025 | |
| Journey Medical Corporation | $73.40 | 2022-2025 | |
| Boston Scientific Corporation | $40.84 | 2025 | Varithena Administration Pack |
| Krystal Biotech INC | $33.68 | 2024 | Vyjuvek |
| Dermira, INC. | $20.21 | 2021 | |
| Organogenesis INC. | $15.85 | 2023 | Puraply |
| Vyne Pharmaceuticals INC. | $15.67 | 2021 | |
| Dermavant Sciences, INC. | $14.00 | 2024 | Vtama |
| Kerecis Limited | $12.90 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Chand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.